Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mignani

Showing results (301-310 of 356) with videos related to

Pageof 36
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 2, 2001
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indenJ Pratt, P Jimonet, G A Bohme, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 7, 2008
Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective studyS Buechner, M Moretti, A P Burlina, et al.
Colloids and Surfaces. B, Biointerfaces|February 8, 2017
Dendrimer-protein interactions versus dendrimer-based nanomedicineDzmitry Shcharbin, Natallia Shcharbina, Volha Dzmitruk, et al.
Biomedicines|April 29, 2025
The Role of Kidney Biopsy in Fabry DiseaseIrene Capelli, Laura Martano, Gian Marco Berti, et al.
European Journal of Medicinal Chemistry|March 29, 2017
Anticancer copper(II) phosphorus dendrimers are potent proapoptotic Bax activatorsSerge Mignani, Nabil El Brahmi, Laure Eloy, et al.
Renal Failure|February 4, 2025
Expanded screening for Fabry disease in patients with chronic kidney disease not on dialysis: a multicenter Italian experienceYuri Battaglia, Federica Baciga, Meilad Shakkour, et al.
Biomedicines|November 27, 2021
Blood Compatibility of Amphiphilic Phosphorous Dendrons-Prospective Drug NanocarriersSimon Suty, Veronika Oravczova, Zuzana Garaiova, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2000
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activityJ M Stutzmann, G A Bohme, A Boireau, et al.
European Journal of Pharmacology|April 11, 1996
Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitroA Boireau, C Malgouris, M C Burgevin, et al.
International Journal of Cardiology|July 18, 2021
ECG-based score estimates the probability to detect Fabry Disease cardiac involvementStefano Figliozzi, Antonia Camporeale, Sara Boveri, et al.
Pageof 36

Showing results (301-310 of 356) with videos related to

Sort By:
Pageof 36
Bioorganic & Medicinal Chemistry Letters|January 2, 2001
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indenJ Pratt, P Jimonet, G A Bohme, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 7, 2008
Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective studyS Buechner, M Moretti, A P Burlina, et al.
Colloids and Surfaces. B, Biointerfaces|February 8, 2017
Dendrimer-protein interactions versus dendrimer-based nanomedicineDzmitry Shcharbin, Natallia Shcharbina, Volha Dzmitruk, et al.
Biomedicines|April 29, 2025
The Role of Kidney Biopsy in Fabry DiseaseIrene Capelli, Laura Martano, Gian Marco Berti, et al.
European Journal of Medicinal Chemistry|March 29, 2017
Anticancer copper(II) phosphorus dendrimers are potent proapoptotic Bax activatorsSerge Mignani, Nabil El Brahmi, Laure Eloy, et al.
Renal Failure|February 4, 2025
Expanded screening for Fabry disease in patients with chronic kidney disease not on dialysis: a multicenter Italian experienceYuri Battaglia, Federica Baciga, Meilad Shakkour, et al.
Biomedicines|November 27, 2021
Blood Compatibility of Amphiphilic Phosphorous Dendrons-Prospective Drug NanocarriersSimon Suty, Veronika Oravczova, Zuzana Garaiova, et al.
Bioorganic & Medicinal Chemistry Letters|June 8, 2000
4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activityJ M Stutzmann, G A Bohme, A Boireau, et al.
European Journal of Pharmacology|April 11, 1996
Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitroA Boireau, C Malgouris, M C Burgevin, et al.
International Journal of Cardiology|July 18, 2021
ECG-based score estimates the probability to detect Fabry Disease cardiac involvementStefano Figliozzi, Antonia Camporeale, Sara Boveri, et al.
Pageof 36